Home
HelpTest Code CIDPI Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Interpretation, Serum
Useful For
Interpretation for CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum
Method Name
Only orderable as part of a profile. For more information see CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum.
Medical Interpretation
Reporting Name
CIDP/NP Interpretation, SSpecimen Type
SerumSpecimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Frozen | 28 days | ||
| Ambient | 72 hours |
Reference Values
Only orderable as part of a profile. For more information see CIDP / Chronic Inflammatory Demyelinating Polyradiculoneuropathy/Nodopathy Evaluation, Serum.
Interpretation
Seropositivity for contactin-1 IgG is consistent with an immune-mediated demyelinating polyradiculoneuropathy/polyradiculopathy.
Seropositivity for neurofascin-155 IgG4 is consistent with an immune-mediated demyelinating polyradiculoneuropathy.
Clinical Reference
1. Dubey D, Honorat JA, Shelly S, et al: Contactin-1 autoimmunity: Serologic, neurologic, and pathologic correlates. Neurol Neuroimmunol Neuroinflamm. 2020 May 27;7(4):e771
2. Cortese A, Lombardi R, Briani C, et al: Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2020 Nov 21;7(1):e639
3. Manso C, Querol L, Mekaouche M, Illa I, Devaux JJ: Contactin-1 IgG4 antibodies cause paranode dismantling and conduction defects. Brain. 2016 Jun;139(Pt 6):1700-1712
4. Le Quintrec M, Teisseyre M, Bec N, et al: Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. Kidney Int. 2021 Dec;100(6):1240-1249
5. Ogata H, Yamasaki R, Hiwatashi A, et al: Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol. 2015 Oct;2(10):960-971
6. Cortese A, Lombardi R, Briani C, et al: Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype. Neurol Neuroimmunol Neuroinflamm. 2020 Nov 21;7(1):e639
7. Querol L, Nogales-Gadea G, Rojas-Garcia R, et al: Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology. 2014 Mar 11;82(10):879-886
8. Shelly S, Klein CJ, Dyck PJB, et al: Neurofascin-155 immunoglobulin subtypes: Clinicopathologic associations and neurologic outcomes. Neurology. 2021;97(24):e2392-e2403
Day(s) Performed
Varies
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
Not ApplicableLOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| CIDPI | CIDP/NP Interpretation, S | 69048-7 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 616444 | CIDP/NP Interpretation, S | 69048-7 |